A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma is a phase 2 interventional study registered as NCT04485949 by Imvax, with 99 participants enrolled, started 2023-03-20 and due to reach its primary completion in 2027-01. Interventions recorded: IGV-001 Cell Immunotherapy, Placebo, Standard of Care (SOC): Radiation Therapy and SOC: Temozolomide.